PE Tech Report


Like this article?

Sign up to our free newsletter

Andera Partners adds partner to Life Sciences team

Andera Partners has appointed Jan Van den Bossche as a partner within Andera Life Sciences, its team specialised in innovative therapeutics and medical devices.

Van den Bossche (44 – KU Leuven) started his career at Petercam, where he was a biotech analyst for over 12 years. He was involved in numerous public and private transactions of Belgian and Dutch biotech companies, such as ThromboGenics, Tigenix, UCB, AMT (Uniqure), IBA, MDxHealth. Prior to joining Andera Partners, he worked for 7 years as a partner at Fund+, a Belgium-based fund investing in the life sciences sector.

The Andera Life Sciences team is now composed of 15 professionals including five partners and three venture partners. Active since 2000, the team has raised over €1.1 billion through its BioDiscovery family of funds and is currently investing from its new BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in more than 75 European and U.S. biotech and medtech companies.

Jan Van den Bossche also becomes the 20th partner of Andera Partners.

Like this article? Sign up to our free newsletter